Haemonetics

HAE

Market cap $2.88B

BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 7, 2026.

VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in market-leading technologies for pulsed field ablation (PFA) and left atrial appendage closure (LAAC) to treat atrial fibrillation.

Invenomic sold 498,317 shares of Haemonetics Corporation in the fourth quarter. The quarter-end position value decreased by $24.29 million due to the sale of all the fund's shares.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

HAE's NexSys PCS adoption and hospital recovery signal growth ahead, but a leveraged balance sheet and stiff competition still cloud the stock's outlook.

The largest contributor was Haemonetics Corp., a medical device company focused on products related to blood collection and management. Another top contributor was Mueller Industries, Inc., an industrial corporation whose holdings manufacture vital goods for important markets. Within materials, the largest detractor during the quarter was Eagle Materials Inc., a provider of heavy construction materials and light building materials to residential and nonresidential markets.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Touchstone Small Cap Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell 2000® Index, for the quarter ended December 31, 2025. The best performing stocks based on relative performance vs. the benchmark during the quarter included White Mountains Insurance Group, Revolve Group Inc. and Haemonetics Corp. The more challenged positions based on relative performance during the quarter included NewMarket Corp., Certara Inc., and Gates Industrial Corp plc.

BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS ®  Plasma Collection System with Persona ®  PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation.